X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution

被引:14
作者
Watabe, Tsuyoshi [1 ]
Terakawa, Yukihiro [1 ]
Watanabe, Kentaro [1 ]
Ohno, Hiroaki [1 ]
Nakano, Hiroaki [1 ]
Nakatsu, Toru [1 ]
Kato, Hiroaki [1 ]
Izumi, Kazuki [2 ]
Kodama, Eiichi [2 ]
Matsuoka, Masao [2 ]
Kitaura, Kazuo [1 ]
Oishi, Shinya [1 ]
Fujii, Nobutaka [1 ]
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan
[2] Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan
基金
日本科学技术振兴机构;
关键词
HIV-1 fusion inhibitor; C-HR-derived peptide; gp41/S138A substitution; hydrophobicity; desolvation energy; IMMUNODEFICIENCY-VIRUS TYPE-1; MOLECULAR-DYNAMICS; PEPTIDE INHIBITOR; 6-HELIX BUNDLE; ENFUVIRTIDE; REPLICATION; EMERGENCE; ENERGIES; BINDING; DOMAIN;
D O I
10.1016/j.jmb.2009.07.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The S138A substitution of fusion inhibitory peptides derived-from the C-terminal heptad repeat (C-HR) of the human immunodeficiency virus type 1 (HIV-1) gp41 leads to enhanced binding affinity to the N-terminal heptad repeat (N-HR). As such, these peptides exhibit highly potent anti-HIV-1 activity. X-ray crystallographic analysis was performed to understand the effect of the substitution on binding affinity. The comparison of the native and S138A crystal structures indicated that the increase in the hydrophobicity of the S138A substitution may aid the stabilization of the N-HR/C-HR complex through additional hydrophobic contacts. Free-energy calculations suggest that the difference between the desolvation free energies of the C-HR-derived peptides with and without the S138A mutation dominates the observed difference in anti-HIV-1 activity. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:657 / 665
页数:9
相关论文
共 50 条
  • [1] Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure
    Chao, Lijun
    Lu, Lu
    Yang, Hengwen
    Zhu, Yun
    Li, Yuan
    Wang, Qian
    Yu, Xiaowen
    Jiang, Shibo
    Chen, Ying-Hua
    PLOS ONE, 2013, 8 (05):
  • [2] An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor
    Venken, Tom
    Krnavek, Daniela
    Muench, Jan
    Kirchhoff, Frank
    Henklein, Petra
    De Maeyer, Marc
    Voet, Arnout
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2011, 79 (11) : 3221 - 3235
  • [3] Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket
    Bai, Yu
    Xue, Huifang
    Wang, Kun
    Cai, Lifeng
    Qiu, Jiayin
    Bi, Shuangyu
    Lai, Luhua
    Cheng, Maosheng
    Liu, Shuwen
    Liu, Keliang
    AMINO ACIDS, 2013, 44 (02) : 701 - 713
  • [4] Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance
    Anastassopoulou, Cleo G.
    Ketas, Thomas J.
    Sanders, Rogier W.
    Klasse, Per Johan
    Moore, John P.
    VIROLOGY, 2012, 428 (02) : 86 - 97
  • [5] A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity
    Su, Shan
    Wang, Qian
    Xu, Wei
    Yu, Fei
    Hua, Chen
    Zhu, Yun
    Jiang, Shibo
    Lu, Lu
    AIDS, 2017, 31 (07) : 885 - 894
  • [6] A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability
    Pan, Chungen
    Cai, Lifeng
    Lu, Hong
    Lu, Lu
    Jiang, Shibo
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (32) : 28425 - 28434
  • [7] Small Molecule Mimetics of an HIV-1 gp41 Fusion Intermediate as Vaccine Leads
    Caulfield, Michael J.
    Dudkin, Vadim Y.
    Ottinger, Elizabeth A.
    Getty, Krista L.
    Zuck, Paul D.
    Kaufhold, Robin M.
    Hepler, Robert W.
    McGaughey, Georgia B.
    Citron, Michael
    Hrin, Renee C.
    Wang, Ying-Jie
    Miller, Michael D.
    Joyce, Joseph G.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (52) : 40604 - 40611
  • [8] Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution
    Shen, Xiaoying
    Dennison, S. Moses
    Liu, Pinghuang
    Gao, Feng
    Jaeger, Frederick
    Montefiori, David C.
    Verkoczy, Laurent
    Haynes, Barton F.
    Alam, S. Munir
    Tomaras, Georgia D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (13) : 5972 - 5977
  • [9] Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins
    Jurado, Samuel
    Cano-Munoz, Mario
    Morel, Bertrand
    Standoli, Sara
    Santarossa, Elisabetta
    Moog, Christiane
    Schmidt, Sylvie
    Laumond, Geraline
    Camara-Artigas, Ana
    Conejero-Lara, Francisco
    JOURNAL OF MOLECULAR BIOLOGY, 2019, 431 (17) : 3091 - 3106
  • [10] ADS-J21 is a novel HIV-1 entry inhibitor targeting gp41
    Liang, Ruiying
    Dou, Dou
    Wang, Chunying
    Huo, Shanshan
    Wu, Yang
    Wang, Juan
    Yu, Zhengsen
    Zhang, Shuomin
    Xu, Jingjing
    Liu, Yue
    Liu, Peng
    Jiang, Shibo
    Yu, Fei
    CURRENT RESEARCH IN MICROBIAL SCIENCES, 2024, 7